A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
Recruiting now · Phase 1
Conditions studied: Non-Small Cell Lung Cancer
In brief
The researchers are doing this study to find out whether the combination of tepotinib and ivonescimab is a safe and effective treatment for people with non-small cell lung cancer (NSCLC) that is positive for METex14 skipping. The researchers will test up to two different doses of tepotinib in combination with ivonescimab to find the best dose of tepotinib that causes few or mild side effects in participants.
Key facts
- Study ID
- NCT07619339
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 16
- Starts
- 2026-05-27
- Expected to finish
- 2029-05-01
- Last updated by the study team
- 2026-06-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey, United States (enrolling)
- Memorial Sloan Kettering Monmouth (All Protocol Activities) — Middletown, New Jersey, United States (enrolling)
- Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey, United States (enrolling)
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ) — Commack, New York, United States (enrolling)
- Memorial Sloan Kettering Westchester (All Protocol Activities) — Harrison, New York, United States (enrolling)
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York, United States (enrolling)
- Memorial Sloan Kettering Nassau (All Protocol Activities) — Uniondale, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.